TNG

Transgene (TNG)

Transgene SA

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:EU:TNG

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/03	14 : 30	GlobeNewswire Inc.	Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou	EU:TNG	Transgene SA
2024/06/03	14 : 30	GlobeNewswire Inc.	Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer	EU:TNG	Transgene SA
2024/06/03	14 : 30	GlobeNewswire Inc.	Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer	EU:TNG	Transgene SA
2024/05/16	00 : 45	GlobeNewswire Inc.	Transgene’s Combined General Meeting of May 15, 2024	EU:TNG	Transgene SA
2024/05/16	00 : 45	GlobeNewswire Inc.	Transgene’s Combined General Meeting of May 15, 2024	EU:TNG	Transgene SA
2024/05/16	00 : 45	GlobeNewswire Inc.	Assemblée Générale Mixte de Transgene du 15 mai 2024	EU:TNG	Transgene SA
2024/05/15	00 : 45	GlobeNewswire Inc.	Transgene provides business and financial update for Q1 2024	EU:TNG	Transgene SA
2024/05/15	00 : 45	GlobeNewswire Inc.	Transgene provides business and financial update for Q1 2024	EU:TNG	Transgene SA
2024/05/15	00 : 45	GlobeNewswire Inc.	Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024	EU:TNG	Transgene SA
2024/04/25	00 : 45	GlobeNewswire Inc.	Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024	EU:TNG	Transgene SA
2024/04/25	00 : 45	GlobeNewswire Inc.	Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024	EU:TNG	Transgene SA
2024/04/25	00 : 45	GlobeNewswire Inc.	Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024	EU:TNG	Transgene SA
2024/04/12	02 : 05	GlobeNewswire Inc.	Document d'enregistrement Universel 2023	EU:TNG	Transgene SA
2024/04/12	00 : 45	GlobeNewswire Inc.	MIse à disposition du document d'enregistrement universel 2023 de Transgene	EU:TNG	Transgene SA
2024/04/12	00 : 45	GlobeNewswire Inc.	Availability of Transgene's 2023 Universal Registration Document	EU:TNG	Transgene SA
2024/04/10	00 : 45	GlobeNewswire Inc.	Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024	EU:TNG	Transgene SA
2024/04/10	00 : 45	GlobeNewswire Inc.	Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024	EU:TNG	Transgene SA
2024/04/10	00 : 45	GlobeNewswire Inc.	Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024	EU:TNG	Transgene SA
2024/03/28	01 : 45	GlobeNewswire Inc.	Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025	EU:TNG	Transgene SA
2024/03/28	01 : 45	GlobeNewswire Inc.	Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025	EU:TNG	Transgene SA
2024/03/28	01 : 45	GlobeNewswire Inc.	Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025	EU:TNG	Transgene SA
2024/03/28	01 : 45	GlobeNewswire Inc.	Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer	EU:TNG	Transgene SA
2024/03/28	01 : 45	GlobeNewswire Inc.	Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources Humaines	EU:TNG	Transgene SA
2024/03/28	01 : 45	GlobeNewswire Inc.	Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer	EU:TNG	Transgene SA
2024/03/19	01 : 45	GlobeNewswire Inc.	Transgene Announces Upcoming Investor Meetings	EU:TNG	Transgene SA
2024/03/19	01 : 45	GlobeNewswire Inc.	Transgene annonce ses prochaines rencontres avec les investisseurs	EU:TNG	Transgene SA
2024/03/19	01 : 45	GlobeNewswire Inc.	Transgene Announces Upcoming Investor Meetings	EU:TNG	Transgene SA
2024/03/06	15 : 30	GlobeNewswire Inc.	Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	EU:TNG	Transgene SA
2024/03/06	15 : 30	GlobeNewswire Inc.	Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	EU:TNG	Transgene SA
2024/03/06	15 : 30	GlobeNewswire Inc.	Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024	EU:TNG	Transgene SA